Dibenzyl phosphate is an organophosphate compound that exists as a colorless liquid at room temperature. It is commonly synthesized through the reaction of phosphorus oxychloride (POCl3) with benzyl alcohol in the presence of a base. It is a versatile reagent used in various applications, including organic synthesis, polymer science, and as an additive in lubricants. The compound exhibits diverse biological effects, including anti-inflammatory and analgesic properties. Research on dibenzyl phosphate often focuses on its potential applications as a pesticide, herbicide, or flame retardant, as well as its environmental impact and toxicology. Due to its unique structural properties, dibenzyl phosphate is often studied as a model compound for understanding the reactivity and behavior of other organophosphate compounds.'
| ID Source | ID |
|---|---|
| PubMed CID | 74189 |
| CHEMBL ID | 1576902 |
| CHEBI ID | 166472 |
| SCHEMBL ID | 51316 |
| Synonym |
|---|
| AC-19490 |
| c14h15o4p |
| CHEBI:166472 |
| y65r35lz0s , |
| einecs 216-602-3 |
| unii-y65r35lz0s |
| dibenzyl phosphate |
| NCGC00090929-01 |
| 1623-08-1 |
| dibenzyl phosphate, 99% |
| dibenzyl hydrogen phosphate |
| MLS001061262 |
| smr001227194 |
| D-1500 |
| phosphoric acid dibenzyl ester |
| FT-0666443 |
| P1120 |
| AKOS005259580 |
| NCGC00090929-02 |
| HMS3039I14 |
| tox21_201050 |
| dtxcid9013402 |
| cas-1623-08-1 |
| NCGC00258603-01 |
| dtxsid1033402 , |
| GEO-00941 |
| dibenzylphosphoric acid |
| FT-0624642 |
| SCHEMBL51316 |
| CHEMBL1576902 |
| dibenzyl hydrogen phosphate # |
| phosphoric acid, bis(phenylmethyl) ester |
| benzyl phosphate, op(och2ph)2oh |
| phosphoric acid, dibenzyl ester |
| mfcd00004775 |
| CS-W008704 |
| SY020955 |
| AS-14708 |
| BCP26465 |
| creatine phosphate disodium impurity 4 |
| Q27294305 |
| EN300-187021 |
| bis(benzyloxy)phosphinic acid |
| Class | Description |
|---|---|
| dialkyl phosphate | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 10.8376 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.6094 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.0009 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 54.7999 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 21.8162 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 15.8489 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| geminin | Homo sapiens (human) | Potency | 0.2593 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||